Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival

被引：0
作者：
Vicente Morales-Oyarvide
Douglas A Rubinson
Richard F Dunne
Margaret M Kozak
Justin L Bui
Chen Yuan
Zhi Rong Qian
Ana Babic
Annacarolina Da Silva
Jonathan A Nowak
Natalia Khalaf
Lauren K Brais
Marisa W Welch
Caitlin L Zellers
Kimmie Ng
Daniel T Chang
Rebecca A Miksad
Andrea J Bullock
Jennifer F Tseng
Richard S Swanson
Thomas E Clancy
David C Linehan
Jennifer J Findeis-Hosey
Leona A Doyle
Jason L Hornick
Shuji Ogino
Charles S Fuchs
Aram F Hezel
Albert C Koong
Brian M Wolpin
机构：
[1] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[2] Wilmot Cancer Institute,Department of Medicine, Division of Hematology and Oncology
[3] University of Rochester Medical Center,Department of Radiation Oncology
[4] Stanford Cancer Institute,Department of Epidemiology
[5] Harvard TH Chan School of Public Health,Department of Pathology
[6] Brigham and Women’s Hospital and Harvard Medical School,Division of Gastroenterology
[7] Hepatology,Department of Hematology and Oncology
[8] and Endoscopy,Department of Surgery
[9] Brigham and Women’s Hospital,Department of Surgery
[10] Beth Israel Deaconess Medical Center and Harvard Medical School,Department of Surgery
[11] Beth Israel Deaconess Medical Center and Harvard Medical School,Department of Pathology
[12] Brigham and Women’s Hospital and Harvard Medical School,Department of Radiation Oncology
[13] University of Rochester Medical Center,undefined
[14] University of Rochester Medical Center,undefined
[15] The University of Texas MD Anderson Cancer Center,undefined
来源：
British Journal of Cancer | 2017年 / 117卷
关键词：
pancreatic cancer; lymph node metastases; staging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1874 / 1882
页数：8
相关论文
共 294 条
[1]  
Allen PJ(2017)Multi-Institutional Validation Study of the American Joint Commission on Cancer (8th Edition) changes for T and N staging in patients with pancreatic adenocarcinoma Ann Surg 265 185-191
[2]  
Kuk D(2015)Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: proposal for a revised N classification for TNM staging Ann Surg Oncol 22 S1187-S1195
[3]  
Castillo CF(2015)Tests of calibration and goodness-of-fit in the survival setting Stat Med 34 1659-1680
[4]  
Basturk O(2008)The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer Pancreas 37 19-24
[5]  
Wolfgang CL(2016)Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2541-2556
[6]  
Cameron JL(2014)Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes Pancreatology 14 289-294
[7]  
Lillemoe KD(2003)Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients Ann Surg 237 74-85
[8]  
Ferrone CR(2015)Reappraisal of nodal staging and study of lymph node station involvement in pancreaticoduodenectomy with the standard international study group of pancreatic surgery definition of lymphadenectomy for cancer J Am Coll Surg 221 367-79 e4
[9]  
Morales-Oyarvide V(2007)Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis World J Surg 31 337-342
[10]  
He J(2017)Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Lancet 38 1011-1024
12345678910